Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX101 in Healthy Volunteers and Overweight or Obese Patients
NCT06545162Phase 1Completed
- Sponsor
- Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CPX101 in Overweight and obesity (7 cohorts), sponsored by Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. Primary endpoints: Safety of CPX101 at 196 days and Tolerability of CPX101 at 196 days. Started Dec 2024; status: completed.
02
Drugs
CPX101
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT06545162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545162.